StocktoriaAclarion, Inc. ACON
Nasdaq · XNAS · stock · Services-Medical Laboratories
Chart by TradingView
4/9
Piotroski F — financial health
4.23
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | $75,730 | $45,724 | $75,404 | $60,444 | $60,292 |
| Gross profit | $6,828 | -$38,934 | -$324 | -$4,854 | -$8,883 |
| Operating income | -$7.1M | -$5.5M | -$4.9M | -$5.6M | -$3.0M |
| Net income | -$7.2M | -$7.0M | -$4.9M | -$7.1M | -$5.0M |
| Operating cash flow | -$7.2M | -$5.3M | -$3.6M | -$4.9M | -$2.4M |
| Free cash flow | -$7.2M | -$5.3M | -$3.6M | — | — |
| Total assets | $13.7M | $2.1M | $2.5M | $2.9M | $1.9M |
| Total liabilities | $837,287 | $1.2M | $3.2M | — | $7.6M |
| Shareholders' equity | $12.8M | $970,057 | -$727,995 | $2.2M | -$12.8M |
| Ratios | |||||
| Gross margin | 9.0% | -85.2% | -0.4% | -8.0% | -14.7% |
| Operating margin | -9312.5% | -12057.2% | -6466.5% | -9201.2% | -4897.9% |
| Net margin | -9551.9% | -15293.8% | -6513.4% | -11694.4% | -8210.5% |
| FCF margin | -9488.6% | -11540.4% | -4836.5% | — | — |
| Return on assets | -52.9% | -329.3% | -199.7% | -242.5% | -262.0% |
| Return on equity | -56.4% | -720.9% | 674.6% | -317.6% | 38.6% |
| Current ratio | 14.81 | 0.71 | 0.40 | 2.47 | 0.10 |
| Revenue growth | 65.6% | -39.4% | 24.8% | 0.3% | — |
Why these scores methodology →
Piotroski F-score: 4/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 4.23 (safe)
- Working capital / assets 0.845
- Retained earnings / assets -4.278
- EBIT / assets -0.516
- Equity / liabilities 15.329
Sector peers
GOOG · MSFT · META · BABA · DIS · HCA · all Services →
Source: SEC EDGAR filings · CIK 0001635077 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.